
Amneal Pharmaceuticals, Inc.
AMRX
Updated: 24/09/2026, 08:07:09
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
No summaries found.
- Share price
- $19.33
- Market cap
- $6.17B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Chirag K. Patel
- Employees
- 8,700
- IPO date
- 07/05/2018
- Beta
- 1.242
- Last dividend
- $0.00
- Day range
- $18.74 – $20.17
- 52-week range
- $9.49 – $21.18
- 1-day performance
- -0.87%
- 1-year performance
- 103.69%
- Current drawdown (1Y)
- -8.71%
- CIK
- 0001723128
- CUSIP
- 03168L105
- ISIN
- US03168L1052
- Created
- 07/12/2025, 02:04:28
- Last update
- 24/09/2026, 08:07:09
Track Amneal Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move AMRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Zacks Investment Research • STOCK • 11/06/2026, 12:17:09
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
PRNewsWire • STOCK • 10/06/2026, 12:09:00
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
MarketBeat • STOCK • 09/06/2026, 17:05:58
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 15:32:09
Is Amneal a Buy Before Rytary Generic Erosion?
Zacks Investment Research • STOCK • 09/06/2026, 15:01:21
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
Zacks Investment Research • STOCK • 05/06/2026, 14:30:34
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
Proactive Investors • STOCK • 04/06/2026, 16:08:06
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
GlobeNewsWire • STOCK • 04/06/2026, 10:00:00
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
Zacks Investment Research • STOCK • 26/05/2026, 15:16:06
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Zacks Investment Research • STOCK • 15/05/2026, 15:46:14
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Zacks Investment Research • STOCK • 15/05/2026, 12:41:29
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Zacks Investment Research • STOCK • 08/05/2026, 14:16:06